Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
Actively Recruiting
Non-small cell lung cancer NSCLC is a disease where cancer cells grow uncontrollably in lung tissues. This trial evaluates whether the investigational drug telisotuzumab vedotin works better than docetaxel and assesses its safety in adults with previously treated NSCLC that overexpresses c-Met. The study is a Phase 3 randomized trial involving about 768 participants worldwide to compare disease activity and side effects of these treatments. Participants will be randomly assigned to receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks, both given as intravenous infusions. Treatment continues until specific discontinuation criteria are met. Those who benefit may have the option to continue treatment through an extension or rollover study. The study aims to compare how these two treatments affect disease progression and survival. During the study, participants will have regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure progression-free survival and overall survival up to about 39 months, along with response rates and quality of life indicators. The study includes detailed safety monitoring and may involve a higher treatment burden than standard care.
Actively Recruiting
This trial evaluates the combination of Navlimetostat BMS-986504, pembrolizumab, and chemotherapy compared to placebo with pembrolizumab and chemotherapy in adults with first-line metastatic non-small cell lung cancer having homozygous MTAP deletion. The study is a randomized, double-blind Phase 23 trial sponsored by Bristol-Myers Squibb, aiming to understand treatment benefits in this specific patient group. Participants must have measurable metastatic NSCLC, no prior systemic therapy for metastatic disease, and meet performance status criteria. Participants receive either Navlimetostat plus pembrolizumab and chemotherapy or placebo plus pembrolizumab and chemotherapy. Chemotherapy may include drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given on specified days at specified doses. Treatment is administered in the first-line metastatic setting, with detailed dosing and combinations determined by study protocols. Randomization assigns participants to one of multiple arms to compare the investigational combination against placebo. Throughout the study, participants are monitored for progression-free survival up to 2 years and 5 years, overall survival up to 5 years, as well as response rates and safety outcomes including adverse events and laboratory abnormalities. Assessments follow RECIST v1.1 criteria with independent and investigator reviews. Safety monitoring includes tracking serious adverse events and treatment-related side effects up to 90 days after treatment ends. The study duration extends to the primary completion date in August 2031, with ongoing evaluations for up to 5 years post-treatment.
Actively Recruiting
Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.
Actively Recruiting
Researchers are evaluating the combination of brenetafusp IMC-F106C plus nivolumab compared to standard nivolumab regimens in people with previously untreated advanced melanoma who are HLA-A*0201-positive. This phase 3, randomized, controlled study aims to understand how these treatments perform in this specific group. The study focuses on improving progression-free survival and overall outcomes for participants with advanced melanoma. Participants are assigned to one of three groups one group receives a low dose of brenetafusp once weekly for 13 weeks, then every two weeks until Week 51, and every four weeks thereafter, along with nivolumab every four weeks another group receives a high dose of brenetafusp on the same schedule plus nivolumab the third group receives nivolumab alone or nivolumab combined with relatlimab every four weeks. The study includes a dose recommendation phase with changes made in November 2025 based on safety and efficacy data. During the study, participants undergo assessments including tumor measurements per RECIST 1.1, BRAF V600 mutation status evaluation, and performance status scoring. Researchers will monitor progression-free survival up to approximately 45 months, overall survival up to 57 months, and record adverse events, immune responses, and quality of life. The study involves regular dosing and long-term follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness of saruparib combined with a physicians choice of androgen receptor pathway inhibitors ARPI compared with a placebo plus ARPI in men who have metastatic hormone-sensitive prostate cancer mHSPC. These men have previously been treated with docetaxel chemotherapy or PSMA-directed lutetium-177 radioligand therapy and show no signs of disease progression, with PSA levels equal to or above 0.2 ngmL. This phase III randomized study aims to measure the impact of these treatments on disease progression. Participants receive either saruparib 60 mg orally once daily along with a chosen ARPI enzalutamide, darolutamide, or abiraterone in 28-day cycles or a placebo plus the same ARPI regimen in similar cycles. The study is double-blind and includes two cohorts, comparing the combined use of saruparib and ARPI against placebo and ARPI. Treatment continues under medical supervision with regular monitoring. During the study, participants undergo evaluations to measure radiographic progression-free survival up to approximately 56 months, along with other outcomes such as overall survival, time to progression, symptomatic skeletal events, PSA progression, and physical function changes. Blood samples and tumor tissue are collected for biomarker analysis. Safety and treatment effects are closely monitored throughout the study, which may last several years.
Actively Recruiting
Researchers are evaluating Datopotamab Deruxtecan Dato-DXd alone and combined with other anticancer drugs in patients with advanced or metastatic solid tumors. This Phase II, open-label, multicenter study uses a modular master protocol to assess safety, tolerability, recommended dosing, and effectiveness across several cancer types including endometrial, gastric, prostate, ovarian, colorectal, urothelial, and biliary tract cancers. The study allows simultaneous evaluation of Dato-DXd in various treatment combinations and disease settings. Participants receive Dato-DXd intravenously as monotherapy or combined with approved or novel anticancer agents, varying by cancer subtype. Treatment combinations include capecitabine, 5-Fluorouracil, prednisoneprednisolone, carboplatin, bevacizumab, volrustomig, rilvegostomig, and cisplatin. Each substudy tests either monotherapy or combination therapy tailored to the tumor type. The study follows participants during treatment and a safety follow-up period, with some treatments administered orally or intravenously depending on the agent. Throughout the approximately one-year study period, participants undergo regular assessments including tumor measurement, adverse event monitoring, pharmacokinetic sampling, and specific biomarker evaluations such as PSA, CA-125, and radiographic progression depending on cancer type. Researchers evaluate outcomes like objective response rate, progression-free survival, disease control, and overall survival. Safety is monitored closely during and up to 28 or 90 days after treatment discontinuation. Participants provide tumor samples for tissue analysis and may consent to optional genetic research.
Actively Recruiting
This trial evaluates the safety and effectiveness of Volrustomig in women with high-risk locally advanced cervical cancer FIGO 2018 stage IIIA to IVA who have not shown disease progression after platinum-based concurrent chemoradiation therapy CCRT. It is a global, randomized, double-blind, placebo-controlled Phase III study designed to assess outcomes in this specific patient population. Participants are randomly assigned in equal numbers to receive either Volrustomig or a placebo via intravenous infusion. The study compares these two groups to explore the potential benefits and risks of Volrustomig as a treatment following CCRT in women with high-risk locally advanced cervical cancer. Women taking part in the study will undergo multiple assessments over up to approximately seven years. Researchers monitor progression-free survival as the primary outcome, along with overall survival, response rates, duration of response, subsequent therapies, and safety. Additional evaluations include tumor progression, pharmacokinetics, immunogenicity, adverse events, and patient-reported symptoms and quality of life. Participants provide tumor samples and undergo regular health evaluations during this period.
1-10 of 11
1